VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO 2016 | Treating advanced/metastatic urothelial carcinoma: recent developments in the BGJ398 clinical trial

Sumanta Pal • 3 Jun 2016
ASCO 2016
Warning: array_filter() expects parameter 1 to be array, bool given in /home/customer/www/vjoncology.com/public_html/wp-content/themes/vj/single.php on line 281

Sumanta Pal, MD of City of Hope, Duarte, CA, discusses the BGJ398 clinical trial in patients with previously treated advanced/metastatic urothelial carcinoma (NCT01004224). He explains that for the past three decades, all that has been available for patients is cisplatin based chemotherapy, and most recently the PD-L1 antibody atezolizumab. However, the main concern surrounds the fact that there are still going to be patients who will not respond to immunotherapy, and since patients progress beyond chemotherapy, more options are now needed.
BGJ398 is a targeted drug that antagonizes FGFR3, which is a compound or a mutation that arises within 20% of patients with bladder cancer. Furthermore, he explains that in a series of 44 patients, there was a 35% response rate, with one patient developing a complete response (CR), which is an impressive outcome in relation to a metastatic disease. Recorded at the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter